supplementary Figures-1,2,3,4 and 5 from KDM6B Counteracts EZH2-Mediated Suppression of <i>IGFBP5</i> to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer

Supplemental Figure 1. KDM6B and KDM6A expression profiles in breast cancer subtypes. Supplemental Figure 2. KDM6A over-expression is not associated with poor clinical outcome. Supplemental Figure 3.KDM6B knockdown does not result in cell death in SKBR3, MDA-MB-415, BT20 and SUM159 cells. Supplemental Figure 4.IGFBP5 is a prognostic factor that predicts poor prognosis in luminal breast cancer patients. Supplemental Figure5.IGFBP5 regulated by KDM6B and its effect on cell survival.